Evidence map›Paper›PMID 27527858›Full record

ArticleOncotarget2016

Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.

Natalie Burrows, Joseph Williams, Brian A Telfer, Julia Resch, Helen R Valentine, Richard J Fitzmaurice, Amanda Eustace, Joely Irlam, Emily J Rowling, Cuong Hoang-Vu and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Natalie BurrowsHypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK.
Joseph WilliamsHypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK.
Brian A TelferHypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK.
Julia ReschExperimental and Clinical Endocrinology, Medizinische Klinik I, Lubeck, Germany.
Helen R ValentineTranslational Radiobiology Group, University of Manchester, Christie Hospital, NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.
Richard J FitzmauriceDepartment of Histopathology, CSB1, Manchester Royal Infirmary, Manchester, UK.
Amanda EustaceTranslational Radiobiology Group, University of Manchester, Christie Hospital, NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.
Joely IrlamTranslational Radiobiology Group, University of Manchester, Christie Hospital, NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.
Emily J RowlingHypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK.
Cuong Hoang-VuMartin Luther University of Halle-Wittenberg, Halle, Salle, Germany.
Catharine M WestTranslational Radiobiology Group, University of Manchester, Christie Hospital, NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.
Georg BrabantExperimental and Clinical Endocrinology, Medizinische Klinik I, Lubeck, Germany.
Kaye J WilliamsHypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK.
University of Manchester · GBUniversity of Lübeck · DEManchester Academic Health Science Centre · GBManchester Royal Infirmary · GBMartin Luther University Halle-Wittenberg · DE

Funding

Medical Research Council G0801525Wellcome Trust
6 · The paper itself

Abstract

Anaplastic (ATC) and certain follicular thyroid-carcinomas (FTCs) are radioresistant. The Phosphatidylinositide 3-kinase (PI3K) pathway is commonly hyperactivated in thyroid-carcinomas. PI3K can modify the PI3K-related kinases (PIKKs) in response to radiation: How PIKKs interact with PI3K and contribute to radioresistance in thyroid-carcinomas is unknown. Further uncertainties exist in how these interactions function under the radioresistant hypoxic microenvironment. Under normoxia/anoxia, ATC (8505c) and FTC (FTC-133) cells were irradiated, with PI3K-inhibition (via GDC-0941 and PTEN-reconstitution into PTEN-null FTC-133s) and effects on PIKK-activation, DNA-damage, clonogenic-survival and cell cycle, assessed. FTC-xenografts were treated with 5 × 2 Gy, ± 50 mg/kg GDC-0941 (twice-daily; orally) for 14 days and PIKK-activation and tumour-growth assessed. PIKK-expression was additionally assessed in 12 human papillary thyroid-carcinomas, 13 FTCs and 12 ATCs. GDC-0941 inhibited radiation-induced activation of Ataxia-telangiectasia mutated (ATM), ATM-and Rad3-related (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Inhibition of ATM and DNA-PKcs was PI3K-dependent, since activation was reduced in PTEN-reconstituted FTC-133s. Inhibition of PIKK-activation was greater under anoxia: Consequently, whilst DNA-damage was increased and prolonged under both normoxia and anoxia, PI3K-inhibition only reduced clonogenic-survival under anoxia. GDC-0941 abrogated radiation-induced cell cycle arrest, an effect most likely linked to the marked inhibition of ATR-activation. Importantly, GDC-0941 inhibited radiation-induced PIKK-activation in FTC-xenografts leading to a significant increase in time taken for tumours to triple in size: 26.5 ± 5 days (radiation-alone) versus 31.5 ± 5 days (dual-treatment). PIKKs were highly expressed across human thyroid-carcinoma classifications, with ATM scoring consistently lower. Interestingly, some loss of ATM and DNA-PKcs was observed. These data provide new insight into the mechanisms of hypoxia-associated radioresistance in thyroid-carcinoma.

Indexed as

AnimalsCarcinomaCarcinoma, PapillaryCell CycleCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsDNA DamageDose-Response Relationship, RadiationEnzyme ActivationFemaleHistonesHumansHypoxiaIndazolesMice2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineCell Cycle ProteinsDNA-Binding ProteinsH2AX protein, humanHistonesIndazolesOxygenPhosphatidylinositol 3-KinasesSulfonamidesATMATRDNA-PKcsPI3Kradioresistance

Identifiers

PMID27527858
PMCPMC5325350
OpenAlexW2482655950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.